The endoplasmic reticulum (ER) is a crucial organelle responsible for protein folding, calcium homeostasis, and lipid synthesis. When the ER experiences an accumulation of misfolded or unfolded —a condition known as ER stress—it triggers a highly conserved adaptive response called the Unfolded Protein Response (UPR). The UPR attempts to restore ER homeostasis by increasing ER chaperone expression, reducing protein translation, and enhancing ER-associated degradation (ERAD). However, when ER stress becomes chronic or overwhelming, the UPR switches from an adaptive to a pro-apoptotic signaling mode, contributing to neuronal death in neurodegenerative [@ron2007][@kim2008].
The UPR is mediated by three ER transmembrane sensors: IRE1 (inositol-requiring enzyme 1), PERK (protein kinase RNA-like ER kinase), and ATF6 (activating transcription factor 6). Under normal conditions, these sensors are bound to the ER chaperone BiP (GRP78), which maintains them in an inactive state. During ER stress, BiP dissociates from these sensors to bind misfolded , thereby activating the UPR signaling pathways[@credle2015][@bertolotti2000].
IRE1 Pathway: IRE1 is a dual-function protein with kinase and endoribonuclease domains. Upon activation, IRE1 undergoes oligomerization and autophosphorylation, leading to the unconventional splicing of XBP1 mRNA. The spliced form of XBP1 (XBP1s) encodes a potent transcription factor that upregulates genes involved in protein folding, ERAlzheimer's disease, and lipid biosynthesis. In neurons, IRE1 signaling has been shown to be particularly important for maintaining ER homeostasis, and its dysregulation contributes to apoptotic cell death[@yoshida2001][@calfon2002].
PERK Pathway: PERK activation leads to phosphorylation of the eukaryotic translation initiation factor eIF2α, resulting in global translation attenuation. This reduces the protein folding burden on the ER. However, selective translation of specific mRNAs continues, including the transcription factor ATF4, which regulates genes involved in amino acid metabolism, antioxidant responses, and apoptosis (such as CHOP). Chronic PERK activation has been implicated in synaptic dysfunction and neuronal loss in Alzheimer's disease[@harding2003][@scheper2013].
ATF6 Pathway: Upon ER stress, ATF6 translocates to the Golgi apparatus, where it is cleaved by proteases S1P and S2P. The cytosolic fragment of ATF6 (ATF6f) acts as a transcription factor, activating genes encoding ER chaperones and XBP1. ATF6 has been shown to have both protective and pathogenic roles depending on the context and duration of ER stress[@haze2004][@yamamoto2007].
ER calcium homeostasis is tightly linked to protein folding capacity. The ER calcium pool is maintained by sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pumps and ryanodine receptors. Calcium depletion from the ER due to excitotoxicity, oxidative stress, or mitochondrial dysfunction can impair ER chaperone function and trigger ER stress. In Alzheimer's disease, amyloid-beta peptides have been shown to perturb ER calcium stores, contributing to ER stress and UPR activation[@paschen2001][@mattson2000].
In Alzheimer's disease, multiple factors contribute to ER stress. Amyloid-beta (Aβ) oligomers induce ER stress in neurons through calcium dysregulation, oxidative stress, and direct interactions with ER chaperones. Postmortem brain studies from Alzheimer's disease patients show elevated levels of phosphorylated IRE1, eIF2α, and ATF6 cleavage products, indicating chronic UPR activation. The PERK-eIF2α pathway has been particularly implicated in synaptic dysfunction and memory deficits in Alzheimer's disease mouse models[@hashimoto2018][@scheper2015][@cornejo2013].
The transcription factor CHOP (GAlzheimer's diseaseD153), downstream of PERK-ATF4 signaling, plays a central role in ER stress-induced apoptosis. CHOP promotes apoptosis by downregulating anti-apoptotic Bcl-2 and enhancing pro-apoptotic Bim expression. In Alzheimer's disease brains, CHOP is upregulated in vulnerable neurons populations, and genetic deletion of CHOP in Alzheimer's disease mouse models ameliorates neurons death and improves cognitive function[@song2008][@leyns2017].
ER stress is a prominent feature of Parkinson's disease, particularly in relation to alpha-synuclein pathology. Mutant α-synuclein (A53T, A30P) accumulates in the ER and interferes with ERAD, leading to chronic ER stress. Studies show that dopaminergic neurons are particularly vulnerable to ER stress due to their high metabolic demand and low antioxidant capacity. In Parkinson's disease brain tissue, markers of UPR activation, including XBP1 splicing and CHOP expression, are significantly elevated[@lindholm2006][@imai2001][@ryu2002].
The PINK1-Parkin mitophagy pathway, critical for mitochondrial quality control, intersects with ER stress signaling. ER stress can impair mitophagy, while mitochondrial dysfunction can exacerbate ER stress, creating a vicious cycle that promotes neurodegeneration. Interestingly, activation of the IRE1-XBP1 pathway has been shown to protect dopaminergic neurons in Parkinson's disease models, suggesting that enhancing adaptive UPR signaling may be therapeutically beneficial[@murata2018][@xia2020].
ER stress is increasingly recognized as a key contributor to motor neuron degeneration in amyotrophic lateral sclerosis. Mutations in SOD1, TDP-43, FUS, and C9orf72 repeat expansions all induce ER stress in model systems. Mutant SOD1 accumulates in the ER and activates all three UPR pathways. In ALS patients, elevated CHOP and BiP expression is observed in motor neurons and astrocytes. The IRE1-XBP1 pathway appears to be particularly important in ALS pathogenesis, and its dysregulation contributes to motor neuron death[@prell2020][@kim2014][@medranosoto2019].
Huntingtin protein (HTT) mutations lead to ER stress through multiple . Mutant huntingtin protein interferes with ERAD and induces calcium dysregulation. The polyglutamine expansion in mutant HTT also disrupts ER-Golgi trafficking. In Huntington's disease mouse models and patient brains, markers of UPR activation are present, and the PERK-eIF2α pathway has been linked to the characteristic striatal neurodegeneration. Interestingly, partial inhibition of PERK signaling has shown promise in HD models, highlighting the complex role of the UPR in disease pathogenesis[@du2021][@ravikumar2010][@leitman2020].
Several small molecules targeting ER stress pathways are in development for neurodegenerative . TUDCA (tauroursodeoxycholic acid) is a hydrophilic bile acid that inhibits CHOP expression and prevents ER stress-induced apoptosis. TUDCA has shown neuroprotective effects in Alzheimer's disease, Parkinson's disease, and HD models and has been evaluated in clinical trials for Amyotrophic lateral sclerosis and Parkinson's disease[@castro2014][@elia2019].
Salubrinal is a selective inhibitor of eIF2α dephosphorylation, thereby maintaining the translational repression during ER stress. While salubrinal shows protective effects in some models, its chronic use can be detrimental due to sustained protein synthesis inhibition. More selective PERK inhibitors, such as GSK2606414, are being developed for Amyotrophic lateral sclerosis and Alzheimer's disease[@boyce2005][@morita2020].
IRE1 inhibitors such as MKC8866 and APY029 inhibit the RNase activity of IRE1, reducing XBP1 splicing and pro-apoptotic signaling. These compounds have shown promise in preclinical models of Alzheimer's disease and Parkinson's disease[@ghosh2014][@logue2020].
Gene therapy strategies targeting ER stress pathways are also being explored. XBP1 overexpression has shown protective effects in Parkinson's disease models by enhancing ERAlzheimer's disease capacity. BDNF delivery can modulate UPR signaling in neurons. CHOP knockdown using siRNA or antisense oligonucleotides represents another therapeutic approach, though its broad inhibition may have unintended consequences given the role of CHOP in normal cellular stress responses[@xue2015][@ng2021].
Enhancing overall proteostasis capacity represents a complementary strategy. ER chaperone induction using compounds such as BIX (BiP inducer X) or GERB (GRP78 inducer) can enhance ER folding capacity. ERAlzheimer's disease enhancement through upregulation of E3 ubiquitin ligases and other ERAlzheimer's disease components helps clear misfolded . Autophagy induction using rapamycin or trehalose can compensate for impaired ERAlzheimer's disease by providing an alternative degradation pathway[@kudo2020][@rothman2012][@senft2016].
The ER stress response intersects with multiple other cellular pathways relevant to neurodegeneration:
| Finding | Disease | Reference |
|---|---|---|
| CHOP deletion improves cognition in Alzheimer's disease mice | Alzheimer's disease | [@song2008] |
| XBP1 deficiency promotes α-synuclein aggregation | Parkinson's disease | [@xia2020] |
| IRE1 RNase inhibition protects against neurodegeneration | Alzheimer's disease/Parkinson's disease | [@ghosh2014] |
| TUDCA slows progression in Amyotrophic lateral sclerosis clinical trial | Amyotrophic lateral sclerosis | [@elia2019] |
| PERK inhibition ameliorates HD pathology | HD | [@ravikumar2010] |
The endoplasmic reticulum (ER) and mitochondria form specialized contact sites called mitochondria-associated membranes (MAMs), which serve as critical hubs for calcium signaling and lipid transfer between these organelles. MAMs facilitate the rapid transfer of calcium from the ER to mitochondria, a process essential for mitochondrial function and ATP production. The distance between ER and mitochondrial membranes at MAMs is approximately 10-30 nm, controlled by tethering including Mfn2, VDAC1, and IP3R[@hayashi2017][@wang2020].
In neurodegenerative , MAM function is significantly disrupted. In Alzheimer's disease, amyloid-β) deposition alters the distribution and function of MAM , leading to abnormal calcium transfer between the ER and mitochondria. This calcium dysregulation causes mitochondrial calcium overload, leading to opening of the mitochondrial permeability transition pore (mPTP), loss of mitochondrial membrane potential, and eventually neurons death. Postmortem studies from Alzheimer's disease brains show increased MAM complexity and altered expression of MAM-tethering [@hedskog2022][@popugaeva2018].
Parkinson's disease models demonstrate that mutant α-synuclein accumulates at MAMs and disrupts the ER-mitochondria connection. This disruption impairs mitochondrial calcium uptake and ATP production, making dopaminergic neurons more vulnerable to stress. PINK1 and Parkin, mutated in familial Parkinson's disease, are recruited to damaged mitochondria and modulate MAM function. The interplay between ER stress and mitochondrial dysfunction at MAMs creates a feed-forward loop that promotes neurodegeneration[@cali2021][@gautier2019].
Detection of ER stress in living patients remains challenging, but several biomarker approaches are being developed. **Cerebrospinal fluid (CSF) ** including BiP (GRP78), CHOP, and XBP1s are elevated in neurodegenerative . In Alzheimer's disease, CSF BiP levels correlate with disease severity and cognitive decline. In Amyotrophic lateral sclerosis, CSF CHOP levels distinguish between disease subtypes and predict progression[@backe2020][@henkel2021].
**Blood-based ** are also being investigated. Soluble forms of the UPR sensors IRE1 and PERK can be detected in blood, though their clinical utility remains to be established. Additionally, measuring the ratio of spliced to unspliced XBP1 in peripheral blood mononuclear cells (PBMCs) provides an indirect measure of UPR activation. These may eventually enable early diagnosis and monitoring of disease progression[@kim2019][@yoshida2020].
The complexity of UPR signaling presents both challenges and opportunities for therapeutic intervention. Biomarker development for patient stratification is essential, as the UPR response varies significantly between individuals and disease stages. Patients with elevated baseline UPR activation may respond differently to treatment than those with minimal activation.
Combination therapies targeting multiple arms of the UPR simultaneously represent a promising approach. For example, combining ER chaperone inducers with autophagy enhancers could address both protein folding and clearance deficits. Similarly, targeting both IRE1 and PERK pathways may provide more comprehensive neuroprotection than single-target approaches.
Personalized medicine based on genetic background may also be relevant. Polymorphisms in UPR genes such as XBP1, ATF6, and PERK may influence disease risk and progression. Understanding how these genetic variants affect UPR signaling could enable more targeted therapeutic interventions[@soo2018][@hetz2017].
ER stress and the unfolded protein response play central roles in the pathogenesis of neurodegenerative including Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, and Huntington's disease. The three sensor pathways (IRE1, PERK, ATF6) provide both adaptive and pro-apoptotic signals, and the balance between these responses determines neurons survival or death. Therapeutic modulation of ER stress pathways represents a promising but challenging approach to neurodegeneration. Current strategies include small molecule UPR modulators, gene therapy approaches, and proteostasis enhancement. As our understanding of ER stress in neurodegeneration deepens, more targeted and effective therapies are likely to emerge.